Isocitrate Dehydrogenase, Patient-Reported Outcomes, and Cognitive Functioning of Glioma Patients: a Systematic Review
- PDF / 374,078 Bytes
- 10 Pages / 595.276 x 790.866 pts Page_size
- 53 Downloads / 202 Views
NEURO-ONCOLOGY (Y UMEMURA, SECTION EDITOR)
Isocitrate Dehydrogenase, Patient-Reported Outcomes, and Cognitive Functioning of Glioma Patients: a Systematic Review Adomas Bunevicius 1,2,3,4
&
Julie Miller 2,5,6 & Michael Parsons 2,5,7
Accepted: 7 September 2020 # Springer Science+Business Media, LLC, part of Springer Nature 2020
Abstract Purpose of Review Isocitrate dehydrogenase (IDH) mutation status has important prognostic implications in glioma patients, with IDH wild-type (IDH-WT) gliomas being associated with worse prognosis and shorter survival when compared with IDH mutant (IDH-mut) gliomas. Optimization of quality of life is a priority in the management of glioma patients. The goal of this systematic review was to identify studies that explored the association of IDH mutation status with patient-reported outcomes (PROs) and cognitive functioning of glioma patients. Recent Findings Studies that evaluated the association of IDH mutation status with PROs and/or cognitive functioning of glioma patients were identified from the Pubmed/MEDLINE, Clarivate analytics, and Google Scholar databases. Eight studies (7 journal articles and 2 conference abstracts) with a total of 658 low-grade glioma and high-grade glioma patients investigated the association of cognitive functioning and/or QoL with IDH status. IDH-WT status was associated with greater cognitive impairment relative to IDH-Mut status in three studies, while one study did not find the association between IDH status and perioperative cognitive functioning. One study reported worse postoperative cognitive functioning patients with IDH-WT vs. IDH-mut gliomas. In one study, IDH-WT status was linked to greater impairment on physical and communication functioning after surgery. Summary IDH-WT gliomas are associated with greater cognitive burden than IDH-Mut tumors. The association of IDH status with QoL remains less clear. Assessment of IDH status should be considered when evaluating QoL and cognitive complaints of glioma patients. Further studies linking glioma molecular phenotypes with PROs and cognitive functioning are encouraged. Keywords Glioma . Isocitrate dehydrogenase . Cognitive functioning . Patient-reported outcomes . Quality of life This article is part of the Topical Collection on Neuro-oncology
Introduction * Adomas Bunevicius [email protected] 1
Department of Neurosurgery, Brigham and Women’s Hospital, Boston, MA, USA
2
Harvard Medical School, Boston, MA, USA
3
Neuroscience Institute, Lithuanian University of Health Sciences, Kaunas, Lithuania
4
Department of Neurosurgery, University of Virginia, 1 Hospital Dr., Charlottesville, VA 22903, USA
5
Pappas Center for Neuro-Oncology, Massachusetts General Hospital, Boston, MA, USA
6
Department of Neurology, Massachusetts General Hospital, Boston, MA, USA
7
Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA
Glioma is the most common malignant intracranial tumor and is a significant source of cancer-related morbidity and mortality worldwide [1, 2]. The prognos
Data Loading...
